Search every filing
2,477,667 paragraphs from 10-Ks, 10-Qs and 8-Ks with press releases.
Matching paragraphs
• restructuring charges of $ 59 million for the year ended March 31, 2025 for restructuring initiatives, as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net;”
Read in the filing ↗ Also in 10-K of May 8, 2026, 10-K of May 9, 2025, 10-K of May 8, 2026
• restructuring charges of $ 61 million for the three months ended June 30, 2026 for restructuring initiatives as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net. ”
Read in the filing ↗
• restructuring charges of $ 67 million for the nine months ended December 31, 2024 for restructuring initiatives as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net;” and
Read in the filing ↗ Also in 10-Q of Feb 4, 2026
• restructuring charges of $ 43 million and $ 204 million for the years ended March 31, 2026 and 2025, respectively, for restructuring initiatives, as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net.”
Read in the filing ↗ Also in 10-K of May 9, 2025, 10-K of May 8, 2026
• restructuring charges of $ 29 million and $ 1 million for the three months ended June 30, 2025 and 2024, respectively, for restructuring initiatives as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net.”
Read in the filing ↗ Also in 10-Q of Aug 5, 2026, 10-Q of Aug 6, 2025
• restructuring charges of $ 18 million and $ 79 million for the three and six months ended September 30, 2026, respectively, for restructuring initiatives as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net.”
Read in the filing ↗ Also in 10-Q of Nov 6, 2025, 10-Q of Nov 6, 2025
• restructuring charges of $ 68 million, $ 55 million, and $ 83 million for the years ended March 31, 2025, 2024, and 2023, respectively, for restructuring initiatives, as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net;”
Read in the filing ↗ Also in 10-K of May 8, 2026
• Restructuring, impairment, and related charges, net of $286 million, are discussed below under “Restructuring Initiatives” as well as Financial Note 3, “Restructuring, Impairment, and Related Charges, Net,” to the consolidated financial statements included in this Annual Report.
Read in the filing ↗ Also in 10-K of May 8, 2026, 10-K of May 8, 2026
(5) The Company’s Medical-Surgical Solutions other segment expense, net for the year ended March 31, 2025 includes restructuring charges of $ 204 million for restructuring initiatives, as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net. ”
Read in the filing ↗
• Restructuring, impairment, and related charges, net of $115 million are primarily related to Corporate expenses, net. Refer to the “Restructuring Initiatives” discussion below as well as Financial Note 3, “ Restructuring, Impairment, and Related Charges, Net,” to the consolidated financial statements included in this Annual Report for more information.
Read in the filing ↗
• restructuring charges of $ 52 million and $ 38 million for the three months ended September 30, 2026 and 2025, respectively, and $ 102 million and $ 67 million for the six months ended September 30, 2026 and 2025, respectively, for restructuring initiatives as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net;”
Read in the filing ↗
• restructuring charges of $ 38 million and $ 23 million for the three months ended September 30, 2025 and 2024, respectively, and charges of $ 67 million and $ 24 million for the six months ended September 30, 2025 and 2024, respectively, for restructuring initiatives as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net.”
Read in the filing ↗ Also in 10-Q of Nov 6, 2025
• restructuring charges of $ 38 million and $ 10 million for the three months ended December 31, 2025 and 2024, respectively, and charges of $ 105 million and $ 34 million for the nine months ended December 31, 2025 and 2024, respectively, for restructuring initiatives as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net.”
Read in the filing ↗ Also in 10-Q of Feb 4, 2026
• Restructuring, impairment, and related charges, net were $47 million and $10 million for the three months ended June 30, 2025 and 2024, respectively, as discussed below under “Restructuring Initiatives.”
Read in the filing ↗ Also in 10-Q of Aug 5, 2026
Refer to Financial Note 3, “Restructuring, Impairment, and Related Charges, Net,” to the accompanying condensed consolidated financial statements included in this Quarterly Report for further information on our restructuring initiatives.
Read in the filing ↗ Also in 10-Q of Nov 6, 2025, 10-Q of Feb 4, 2026, 10-Q of Aug 5, 2026, 10-Q of Nov 4, 2026
Restructuring Charges: We have certain restructuring reserves which require significant estimates related to the timing and amount of future employee severance and other exit-related costs to be incurred when the restructuring actions take place. We generally recognize employee severance costs when payments are probable and amounts can be reasonably estimated. Costs related to contracts without future benefit or contract termination are recognized at the earlier of the contract termination or the cease-use dates. Other exit-related costs are expensed as incurred. In connection with these restructuring actions, we also assess the recoverability of long-lived assets used in the business, and as a result, we may recognize accelerated depreciation and amortization reflecting shortened useful lives of the underlying assets. Refer to Financial Note 3, “ Restructuring, Impairment, and Related Charges, Net,” to the consolidated financial statements included in this Annual Report for additional information on restructuring matters.
Read in the filing ↗ Also in 10-K of May 8, 2026
• restructuring charges of $ 43 million in fiscal 2023 primarily for severance and employee-related costs, as well as asset impairments and accelerated depreciation. Refer to Financial Note 3, “ Restructuring, Impairment, and Related Charges, Net” for further information.
Read in the filing ↗
• For the year ended March 31, 2025, we recorded restructuring charges of $298 million related to an enterprise-wide initiative to drive operational efficiencies as further described in the “Restructuring Initiatives” section of “Overview of Consolidated Results” below;
Read in the filing ↗ Also in 10-K of May 8, 2026
• charges of $61 million for the three months ended June 30, 2026 for restructuring initiatives as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net,” to the accompanying condensed consolidated financial statements included in this Quarterly Report;
Read in the filing ↗
We recorded restructuring, impairment, and related charges of $286 million and $115 million for the years ended March 31, 2025 and 2024, respectively. These charges were included in “Restructuring, impairment, and related charges, net” in the Consolidated Statements of Operations.
Read in the filing ↗ Also in 10-K of May 8, 2026
We recorded restructuring, impairment, and related charges of $47 million and $10 million for the three months ended June 30, 2025 and 2024, respectively. These charges were included in “Restructuring, impairment, and related charges, net” in the Condensed Consolidated Statements of Operations.
Read in the filing ↗ Also in 10-Q of Aug 5, 2026, 10-Q of Nov 6, 2025, 10-Q of Feb 4, 2026, 10-Q of Nov 4, 2026
The Company recorded restructuring, impairment, and related charges, net of $ 47 million and $ 10 million for the three months ended June 30, 2025 and 2024, respectively. These charges were included in “Restructuring, impairment, and related charges, net” in the Condensed Consolidated Statement of Operations.
Read in the filing ↗
• charges of $50 million and $29 million for the three months ended June 30, 2026 and 2025 for restructuring initiatives as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net,” to the accompanying condensed consolidated financial statements included in this Quarterly Report;
Read in the filing ↗
The Company recorded total restructuring, impairment, and related charges, net of $ 136 million and $ 47 million for the three months ended June 30, 2026 and 2025, respectively. These charges were included in “Restructuring, impairment, and related charges, net” in the Condensed Consolidated Statement of Operations.
Read in the filing ↗ Also in 10-Q of Nov 4, 2026
• charges of $18 million and $79 million for the three and six months ended September 30, 2026, respectively, for restructuring initiatives as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net,” to the accompanying condensed consolidated financial statements included in this Quarterly Report;
Read in the filing ↗
• Restructuring, impairment, and related charges, net were $63 million and $171 million for the three months ended September 30, 2025 and 2024, respectively, and $110 million and $181 million for the six months ended September 30, 2025 and 2024, respectively, as discussed below under “Restructuring Initiatives.”
Read in the filing ↗ Also in 10-Q of Nov 4, 2026
• Restructuring, impairment, and related charges, net were $36 million and $32 million for the three months ended December 31, 2025 and 2024, respectively, and $146 million and $213 million for the nine months ended December 31, 2025 and 2024, respectively, as discussed below under “Restructuring Initiatives.”
Read in the filing ↗
… The restructuring programs may be implemented due to the sale or discontinuation of a product line, reorganization or management structure changes, headcount rationalization, realignment of operations or products, integration of acquired businesses, and/or company-wide cost saving initiatives. The amount and/or frequency of these restructuring charges are not part of the Company’s underlying business, which include normal …
Read in the filing ↗ Also in 10-K of May 8, 2026
(5) The Company’s Medical-Surgical Solutions other segment expense, net for the three and six months ended September 30, 2024 includes restructuring charges of $ 144 million related to a broad set of initiatives to drive operational efficiencies and increase cost optimization efforts as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net.”
Read in the filing ↗
• restructuring charges of $43 million and $204 million for the years ended March 31, 2026 and 2025, respectively, related to a broad set of initiatives to drive operational efficiencies and increase cost optimization efforts, as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net,” to the consolidated financial statements included in this Annual Report.
Read in the filing ↗
Restructuring, impairment, and related charges, net for the year ended March 31, 2025 consisted of the following:
Read in the filing ↗ Also in 10-K of May 9, 2025, 10-K of May 9, 2025, 10-K of May 8, 2026, 10-K of May 8, 2026, 10-K of May 8, 2026
(5) The Company’s Medical-Surgical Solutions other segment expense, net for the three and nine months ended December 31, 2024 includes restructuring charges of $ 19 million and $ 169 million, respectively, related to a broad set of initiatives to drive operational efficiencies and increase cost optimization efforts as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net.”
Read in the filing ↗
The Company recorded restructuring, impairment, and related charges, net of $ 344 million, $ 115 million, and $ 209 million in fiscal 2025, fiscal 2024, and fiscal 2023, respectively. Of these charges $ 286 million were included in “Restructuring, impairment, and related charges, net” and $ 58 million was included in “Cost of sales” in the Consolidated Statement of Operations for the year ended March 31, 2025.
Read in the filing ↗ Also in 10-K of May 8, 2026
Restructuring, impairment, and related charges - Restructuring charges that are incurred for programs in which we change our operations, the scope of a business undertaken by our business units, or the manner in which that business is conducted as well as long-lived asset impairments. Such charges may include employee severance, retention bonuses, facility closure or consolidation costs, lease or contract termination costs, asset impairments, accelerated depreciation and amortization, and other related expenses. The restructuring programs may be implemented due to the sale or discontinuation of a product line, reorganization or management structure changes, headcount rationalization, realignment of operations or products, integration of acquired businesses, and/or company-wide cost saving initiatives. The amount and/or frequency of these restructuring charges are not part of our underlying business, which include normal levels of reinvestment in the business. Any credit adjustments due to subsequent changes in estimates are also excluded from adjusted results.
Read in the filing ↗ Also in 8-K of Feb 7, 2024, 8-K of May 7, 2024, 8-K of Aug 7, 2024, 8-K of Nov 6, 2024, 8-K of Feb 5, 2025, 8-K of May 8, 2025, 8-K of Aug 6, 2025, 8-K of Sep 18, 2025, 8-K of Nov 5, 2025, 8-K of Feb 4, 2026, 8-K of May 7, 2026, 8-K of Aug 5, 2026, 8-K of Nov 4, 2026
Restructuring, impairment, and related charges, net for the three months ended June 30, 2025 and 2024 consisted of the following:
Read in the filing ↗ Also in 10-Q of Aug 5, 2026
Restructuring, impairment, and related charges, net for the three months ended September 30, 2025 and 2024 consisted of the following:
Read in the filing ↗ Also in 10-Q of Nov 4, 2026
Restructuring, impairment, and related charges, net for the six months ended September 30, 2025 and 2024 consisted of the following:
Read in the filing ↗ Also in 10-Q of Nov 4, 2026
Restructuring, impairment, and related charges, net for the three months ended December 31, 2025 and 2024 consisted of the following:
Read in the filing ↗
Restructuring, impairment, and related charges, net for the nine months ended December 31, 2025 and 2024 consisted of the following:
Read in the filing ↗
• charges of $52 million and $38 million for the three months ended September 30, 2026 and 2025, respectively, and charges of $102 million and $67 million for the six months ended September 30, 2026 and 2025, respectively, for restructuring initiatives as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net,” to the accompanying condensed consolidated financial statements included in this Quarterly Report;
Read in the filing ↗
(4) Other segment expense, net for our Medical-Surgical Solutions segment for the nine months ended December 31, 2024 includes restructuring charges of $169 million related to a broad set of initiatives to drive operational efficiencies and increase cost optimization efforts as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net,” to the accompanying condensed consolidated financial statements included in this Quarterly Report.
Read in the filing ↗
discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net,” to the consolidated financial statements included in this Annual Report.
Read in the filing ↗
(4) Other segment expense, net for our Medical-Surgical Solutions segment for the three and six months ended September 30, 2024 includes restructuring charges of $144 million related to a broad set of initiatives to drive operational efficiencies and increase cost optimization efforts as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net,” to the accompanying condensed consolidated financial statements included in this Quarterly Report.
Read in the filing ↗
Refer to Financial Note 3, “Restructuring, Impairment, and Related Charges, Net,” to the consolidated financial statements included in this Annual Report for more information.
Read in the filing ↗ Also in 10-K of May 8, 2026
Gross profit for the year ended March 31, 2025 was impacted by an inventory impairment charge of $58 million related to restructuring initiatives to drive operational efficiencies and increase cost optimization efforts as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net,” to the consolidated financial statements in this Annual Report. We recorded this amount within "Cost of sales" in the Consolidated Statements of Operations within our North American Pharmaceutical segment.
Read in the filing ↗
In addition to assets and liabilities that are measured at fair value on a recurring basis, the Company’s assets and liabilities are also subject to nonrecurring fair value measurements. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges, including long-lived assets associated with the Company’s restructuring initiatives as discussed in more detail in Financial Note 3, “Restructuring, Impairment, and Related Charges Net. ”
Read in the filing ↗ Also in 10-Q of Nov 4, 2026